PURPOSE: The aim of this study was to compare toxicities, disease control, survival outcomes, and patterns of failure between groups of limited-stage small-cell lung cancer patients treated with once-daily versus twice-daily radiotherapy and concurrent chemotherapy. MATERIALS AND METHODS: This single-institution retrospective analysis included a comparison of two of radiotherapy regimens to planned doses of (1) > or =59.4 Gy at 1.8-2.0 Gy per once-daily fraction or (2) > or =45 Gy at 1.5 Gy per twice-daily fractions with concurrent platinum-based chemotherapy. Comparative analyses of toxicities and disease control were performed. RESULTS: A total of 71 patients were included in the present study (17 once-daily, 54 twice-daily). Patient, tumor, staging, and treatment factors were similar between the two treatment groups. Median planned radiotherapy doses were 60 Gy (range 59.4-70.0 Gy) and 45 Gy (range 45-51 Gy) for the once-daily and twice-daily groups, respectively. Acute toxicities were similar between the groups ( approximately 20% grade 3 esophagitis). At a median survival follow-up of 26.2 months (range 3.4-85.5 months), 42 patients had died. The 2-year overall survival estimates were similar at 43% and 49% for the once-daily versus twice-daily groups, respectively. Isolated in-field failures were similar between the two groups ( approximately 17%). CONCLUSION: The present analysis did not detect a statistically significant difference in acute toxicities, disease control, or survival outcomes in limited-stage small-cell lung cancer patients treated with concurrent chemotherapy and once-daily versus twice-daily radiotherapy.
PURPOSE: The aim of this study was to compare toxicities, disease control, survival outcomes, and patterns of failure between groups of limited-stage small-cell lung cancerpatients treated with once-daily versus twice-daily radiotherapy and concurrent chemotherapy. MATERIALS AND METHODS: This single-institution retrospective analysis included a comparison of two of radiotherapy regimens to planned doses of (1) > or =59.4 Gy at 1.8-2.0 Gy per once-daily fraction or (2) > or =45 Gy at 1.5 Gy per twice-daily fractions with concurrent platinum-based chemotherapy. Comparative analyses of toxicities and disease control were performed. RESULTS: A total of 71 patients were included in the present study (17 once-daily, 54 twice-daily). Patient, tumor, staging, and treatment factors were similar between the two treatment groups. Median planned radiotherapy doses were 60 Gy (range 59.4-70.0 Gy) and 45 Gy (range 45-51 Gy) for the once-daily and twice-daily groups, respectively. Acute toxicities were similar between the groups ( approximately 20% grade 3 esophagitis). At a median survival follow-up of 26.2 months (range 3.4-85.5 months), 42 patients had died. The 2-year overall survival estimates were similar at 43% and 49% for the once-daily versus twice-daily groups, respectively. Isolated in-field failures were similar between the two groups ( approximately 17%). CONCLUSION: The present analysis did not detect a statistically significant difference in acute toxicities, disease control, or survival outcomes in limited-stage small-cell lung cancerpatients treated with concurrent chemotherapy and once-daily versus twice-daily radiotherapy.
Authors: J P Pignon; R Arriagada; D C Ihde; D H Johnson; M C Perry; R L Souhami; O Brodin; R A Joss; M S Kies; B Lebeau Journal: N Engl J Med Date: 1992-12-03 Impact factor: 91.245
Authors: Xiong Wei; H Helen Liu; Susan L Tucker; Zhongxing Liao; Chaosu Hu; Radhe Mohan; James D Cox; Ritsuko Komaki Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-12 Impact factor: 7.038
Authors: Gregory M M Videtic; José S A Belderbos; Feng-Ming Spring Kong; Lucyna Kepka; Mary K Martel; Branislav Jeremic Journal: Int J Radiat Oncol Biol Phys Date: 2008-10-01 Impact factor: 7.038
Authors: N C Choi; J E Herndon; J Rosenman; R W Carey; C T Chung; S Bernard; L Leone; S Seagren; M Green Journal: J Clin Oncol Date: 1998-11 Impact factor: 44.544
Authors: W Sause; P Kolesar; I V Taylor S; D Johnson; R Livingston; R Komaki; B Emami; W Curran; R Byhardt; A R Dar; A Turrisi Journal: Chest Date: 2000-02 Impact factor: 9.410
Authors: Ritsuko Komaki; R Suzanne Swann; David S Ettinger; Bonnie S Glisson; Alan B Sandler; Benjamin Movsas; John Suh; Roger W Byhardt Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-01 Impact factor: 7.038
Authors: B Movsas; J Moughan; R Komaki; H Choy; R Byhardt; C Langer; M Goldberg; M Graham; D Ettinger; D Johnstone; R Abrams; R Munden; G Starkschall; J Owen Journal: J Clin Oncol Date: 2003-11-03 Impact factor: 44.544
Authors: Peter Paximadis; Jennifer L Beebe-Dimmer; Julie George; Anne G Schwartz; Antoinette Wozniak; Shirish Gadgeel Journal: Clin Lung Cancer Date: 2018-03-23 Impact factor: 4.785
Authors: Amir Zahra; Tangel Chang; Taher Abu Hejleh; Muhammad Furqan; Gerald H Clamon; Sudershan K Bhatia; John M Watkins; Sarah L Mott; Logan L Ahmann; Kellie L Bodeker; Douglas R Spitz; John M Buatti; Bryan G Allen Journal: J Oncol Transl Res Date: 2016-07-26
Authors: Joseph K Salama; Lydia Hodgson; Herbert Pang; James J Urbanic; A William Blackstock; Steven E Schild; Jeffrey Crawford; Jeffrey A Bogart; Everett E Vokes Journal: J Thorac Oncol Date: 2013-08 Impact factor: 15.609
Authors: John M Watkins; J Kyle Russo; Nicholas Andresen; Coyt R Rountree; Amir Zahra; Sarah L Mott; Daniel J Herr; Jacy O'Keefe; Bryan G Allen; Anand K Sharma; John M Buatti Journal: Rep Pract Oncol Radiother Date: 2020-04-27